Chimerix Inc (NASDAQ:CMRX) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 912,900 shares, a growth of 11.2% from the June 30th total of 821,300 shares. Based on an average daily volume of 427,600 shares, the days-to-cover ratio is currently 2.1 days. Approximately 2.1% of the company’s stock are short sold.

Chimerix stock traded down $0.15 during mid-day trading on Thursday, hitting $2.54. 243,390 shares of the stock were exchanged, compared to its average volume of 447,937. Chimerix has a 12 month low of $1.74 and a 12 month high of $4.40. The firm’s fifty day moving average price is $3.55. The firm has a market capitalization of $164.82 million, a PE ratio of -1.78 and a beta of 1.24.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.18). Chimerix had a negative return on equity of 37.18% and a negative net margin of 729.02%. The firm had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.30 million. On average, research analysts expect that Chimerix will post -1.04 earnings per share for the current year.

CMRX has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Chimerix from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. HC Wainwright raised their price target on shares of Chimerix from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Cowen reiterated a “hold” rating and set a $3.00 target price on shares of Chimerix in a research report on Thursday, May 9th. Finally, ValuEngine upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $4.00.

In related news, CEO Michael A. Sherman acquired 30,000 shares of the company’s stock in a transaction dated Monday, May 20th. The shares were bought at an average cost of $3.48 per share, with a total value of $104,400.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Martha J. Demski acquired 18,000 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was bought at an average cost of $3.60 per share, for a total transaction of $64,800.00. The disclosure for this purchase can be found here. Corporate insiders own 9.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Quantitative Systematic Strategies LLC bought a new position in Chimerix during the 2nd quarter worth approximately $67,000. SG Americas Securities LLC raised its holdings in Chimerix by 105.4% during the 1st quarter. SG Americas Securities LLC now owns 20,590 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 10,567 shares during the last quarter. Prudential Financial Inc. bought a new position in Chimerix during the 2nd quarter worth approximately $104,000. Algert Global LLC bought a new position in Chimerix during the 2nd quarter worth approximately $194,000. Finally, Wells Fargo & Company MN raised its holdings in Chimerix by 82.5% during the 2nd quarter. Wells Fargo & Company MN now owns 60,574 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 27,378 shares during the last quarter. Hedge funds and other institutional investors own 69.53% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Read More: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.